Arturo Orlacchio, PhD
RAC-Drugs · ASQ CSSBB
Translational Science Drug Development Biomarker Strategy
Connecting discovery biology, biomarkers, and preclinical development.
12+ years across oncology, in vivo pharmacology, molecular diagnostics, and early drug development.
I work across target validation, mechanism-of-action studies, in vivo pharmacology, biomarker development, and analytical validation. My experience includes support for two New York State CLEP submissions and current responsibility for assay strategy, lead optimization, translational pharmacology, and nonclinical development planning.
I combine scientific depth with structured execution, including experimental design, CRO and vendor coordination, reproducible data analysis, SOPs, QC frameworks, and development-focused documentation.
Core Expertise
-
Translational & Preclinical Development
Model strategy, mechanism-of-action studies, in vivo pharmacology, lead-optimization support, and nonclinical planning. -
Biomarkers & Molecular Diagnostics
Biomarker discovery, analytical validation, IHC, chromatin accessibility, NGS, liquid biopsy, and CDx-relevant assay development. -
Rigorous Program Execution
Quality by Design, reproducible Python workflows, statistical process control, CRO coordination, SOPs, and QC systems.